Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

#4622

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Aim(s): This study aimed to identify the function of HMGB3 in PanNET progression and characterise its protein interactome.

Materials and methods: We analysed the HMGB3 protein interactome using a proximity-dependent biotin identification (Bio-ID) assay. We assessed its functional role using both the gain-of-function and loss-of-function approaches.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,